Human stem cells to model congenital heart disease

On the use of human pluripotent stem cell (hPSC) systems to study cellular and molecular mechanisms of cardiac cell fate and to understand disease mechanisms in the early human heart.

Go to the profile of Thamarasee Jeewandara
Jan 18, 2017
Upvote 3 Comment

Two recent articles, on the necessity of scientific engagement and on safeguarding science1, mutually aim to raise awareness on many fronts in 2017, including innovations of biomedical research. One such innovation, of personal interest, is stem cell therapy for heart disease, which offers potential to understand disease mechanisms and reverse pathological effects of what was once considered terminal heart damage2. Stem-cell-based advances in cardiovascular medicine are twofold; 1) as a cellular resource for therapeutic regeneration of adult failing hearts, and 2) as a research system to model inherited disease of the developing heart3,4. The focus here is on the field of human pluripotent stem cells (hPSCs)5, which includes human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs), with diverse medical applications6,7. This post highlights applications of stem-cell-based models to understand congenital (inherited) heart disease (CHD), the most common human birth defect4, and outlines breakthrough technologies in biology6,7.

Prior to noting in-lab experiments and clinical applications in cardiovascular medicine, a few developmental biology terms are recapped for clarity. Briefly, three basic categories of cells; germ, somatic and stem comprise the mammalian body, and cellular differentiation is simply defined as the change of cell fate from one cell type to another8. Both somatic and germ cells originate from pluripotent cells of the embryo, and the possibility exists to deliberately reprogram cells from one tissue type to another in-lab, via treatment with defined factors6. Mature somatic cells can thus be reprogrammed back to pluripotency (ability to form any cell type) via recently developed induced pluripotent stem cell (iPSC) technology, creating exciting approaches in basic research and regenerative medicine4,6. Prior to this development, differentiation was assumed to be a ‘one-way street’ process from an immature, stem or progenitor cell state, to mature differentiation alone9. The ‘cell-nuclear reprogramming’ technology therefore demonstrates that mature somatic cells retain all genetic information, enabling re-acquisition of pluripotency7,9 (Figure 1). Classical animal models have contributed tremendously at the beginning to evaluate disease mechanisms6 and continue to do so, although they are limited by the accuracy of recapitulation of human disease. Here the focus is entirely on human stem-cell-based CHD models.

Simplified and modified illustration of Waddington's epigenetic landscape

Figure 1: Simplified summary of cell fate changes: pluripotent stem cells (top) can differentiate into somatic cells (left and right) during development and due to various extrinsic cues in cell culture (normal development). Mature somatic cells can be directly converted to another somatic cell fate in the presence of tissue-specific transcription factors (trans-differentiation). A small set of reprogramming factors can reverse differentiated somatic cells back to pluripotency (induction of pluripotency). Figure modified and reproduced from7,9.

While CHD is the most common human birth defect at present with known contribution of genetic and environmental stressors, mechanisms of its etiology (origin) remain an enigma2,4. To understand CHD mechanisms, it is possible to first obtain patient-specific skin cells or blood samples (as a somatic cell source), reprogram them to pluripotent stem cells using a small set of reprogramming factors and then differentiate those cell-forms to create heart muscle cells known as cardiomyocytes (CM) in a Petri dish, at the lab (Figure 2)4,6. The protocol resulted in functional, spontaneously beating heart muscle cells with features characteristic to physiological CMs of the heart4.

Simplified and modified illustration of iPSC technology based cardiomyocyte reprogramming

Figure 2: 1) Isolating patient-specific somatic cells (blood or skin) 2) reprogramming them using core factors to generate induced pluripotent stem cell lines (iPSCs) 3) directed differentiation of iPSCs to form cardiomyocytes (hiPSC-CMs/CMs) 4) phenotypic assays to characterize pathophysiology of individual CHD. The cell types outlined in blue and red are used to build disease model systems listed in table 1. Figure modified and reproduced from4.

These heart muscle cells also represent a viable cell source for functional cardiac tissue engineering applications, to create well-defined heart tissue and regenerate/repair injured heart muscle10. Similarly, disease-specific model systems can be developed with patient-derived iPSCs and CMs to understand various phenotypic forms of CHD and have enabled evaluation of gene regulation, cell-cell and tissue interactions in several clinical studies (Table 1). A few of the disease models also allow direct testing of therapeutic drugs, without exposing the subject to risk for cell-based therapy strategies4,11.

Table 1: Various forms of congenital heart disease (CHD) were modeled in-lab using patient-specific human induced pluripotent stem cell (hiPSC) and human induced pluripotent stem cell differentiated to cardiomyocytes (hiPSC-CM). Table modified from reference4; definition of disease linked to U.S. National Library of Medicine.

Form of CHD modeled in-lab

Characteristics of disease model system


Long QT syndrome (LQTS) types I-III,8 (Timothy Syndrome)

LQTS-specific iPSC-CMs to study cardiac ion channel disorders (channelopathies) and drug responses to develop personalized medicine


Barth Syndrome

Modeling mitochondrial cardiomyopathy with patient-specific iPSC-CMs and heart-on-chip technologies to characterize Barth syndrome.


Catecholaminergic polymorphic ventricular tachycardia (CPVT)

Modelling disease mechanisms with patient-specific iPSCs, to optimize patient care and aid in the development of new therapies.


Pompe Syndrome

Patient-specific iPSCs for pathogenesis modeling, drug testing and disease marker identification.


Arrhythmogenic right ventricular dysplasia (adult-onset disease).

Patient-specific iPSCs to induce adult-like metabolism in establishing adult-onset disease model for pathogenic insights and therapeutic strategies.


Friedreich ataxia (FRDA)

Patient-specific iPSC-CMs and neurons as a model to study mitochondrial and genetic defects in FRDA.


Critical congenital heart disease (CCHD) – hypoplastic left heart syndrome (HLHS)

Patient-specific iPSC-CMs to model HLHS and evaluate contributing fetal gene expression patterns and functional anomalies.


Noonan Syndrome (LEOPARD Syndrome)

Patient-specific iPSC-CMs to understand molecular signaling pathways and contribution to hypertrophic cardiomyopathy.


Most importantly these clinical studies in CHD uncovered patient-specific, molecular target pathways for potential therapeutic strategies in personalized and precision cardiovascular medicine14,15. Unlike human embryonic stem cells derived from blastocysts or fertilized eggs, the iPSC technology offers an experimental approach that lacks the ethical concern of cellular origin, by reprogramming mature somatic cells to induced pluripotency, for stem-cell-based models of CHD7,19. However, by definition, this technology is not applicable to stem-cell-based research avenues studying early human development, vaccine development and viral disease mechanisms20. A setback to the original iPSC protocol was when the process of reprogramming shared common events with carcinogenesis as observed in iPSC derived from experimental animal models, thereafter replaced with modern alternatives19 .

The in-lab stem-cell-based CHD modeling systems are yet far from ideal, as they are limited by complex inheritance gene dosage effects, phenotypic variations of CHD and intricate development processes of the embryonic heart4,18. While at present it isn't possible to accurately model the entire complexity of interactions at the molecular and cellular level in the lab, the system does allow dissection of some processes for an accurate glimpse to pathophysiological mechanisms and complements existing approaches using animal models, to collaboratively address mechanisms in CHD4,10. The technology is regularly optimized to form a universal protocol for large-scale, reproducible and efficient clinical-grade cell production, with hopes for commercialization in clinical, pharmaceutical, tissue engineering and in vitro organ development applications21,22 (Figure 3). Further advances in iPSC technology have found notable recent applications in regenerative medicine; including 1) integration of CMs on a native cardiac extra cellular matrix (ECM) scaffold, to bioengineer a functional human heart with electrical conductivity and metabolic function, in the lab23 and 2) the generation of epicardial cells (cells of external heart surface) under controlled conditions in-lab, with ability to invade and regenerate cells of the myocardium in an infarcted mouse model (in vivo)24.

Immunostaining for structural characterization of cardiomyocytes generated from hPSCsFigure 3: Cardiomyocytes (heart muscle cells), generated in-lab from iPSCs using the protocol described in ref. 21 (Immunostaining for structural characterization: green – actin filaments, red- myosin filaments, blue – cell nuclei). Figure reproduced from ref. 21.

Many biomedical research efforts in the past have accumulated to realize present advancements in cardiac cell therapy. Ongoing research on congenital heart disease with stem cells and animal models will be vital to understand disease mechanisms, develop therapeutic drugs targeting those pathways to reverse CHD progression and ensure healthy heart development for improved quality of life25.

Poster Image: iPSC-CMs labeled with a-Actinin and Cx43, available via the research Image Gallery, Dubois Lab, Icahn School of Medicine, Mount Sinai, New York.


  1. Safeguarding science. Nature medicine 23, 1-1, (2017).
  2. Bernstein, H. S. & Srivastava, D. Stem cell therapy for cardiac disease. Pediatr. Res 71, 491-499 (2012).
  3. Matsa, E., Burridge, P. W. & Wu, J. C. Human stem cells for modeling heart disease and for drug discovery. Sci. transl. med. 6, 1-7, (2014).
  4. Doyle, M. J. et al. Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes as a Model for Heart Development and Congenital Heart Disease. Stem. cell. rev. 11, 710-727, (2015).
  5. Zhu, Z. & Huangfu, D. Human pluripotent stem cells: an emerging model in developmental biology. Development 140, 705-717, (2013).
  6. Takahashi, K. & Yamanaka, S. Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors. Cell 126, 663-676, (2006).
  7. Takahashi, K. & Yamanaka, S. Induced pluripotent stem cells in medicine and biology. Development 140, 2457-2461, (2013).
  8. Slack, J. M. W. Metaplasia and transdifferentiation: from pure biology to the clinic. Nat Rev Mol. Cell. Biol. 8, 369-378 (2007).
  9. Waddington, C. H. The strategy of the genes. A discussion of some aspects of theoretical biology. With an appendix by H. Kacser. (London: George Allen & Unwin, Ltd., 1957).
  10. Cashman, T. J. et al. Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy. JOVE. 1-12, (2016).
  11. Egashira, T. et al. Disease characterization using LQTS-specific induced pluripotent stem cells. Cardiovas. Res. 95, 419-429, (2012).
  12. Wang, G. et al. Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies. 20, 616-623, (2014).
  13. Itzhaki, I. et al. Modeling of catecholaminergic polymorphic ventricular tachycardia with patient-specific human-induced pluripotent stem cells. JACC. 60, 990-1000, (2012).
  14. Huang, H. P. et al. Human Pompe disease-induced pluripotent stem cells for pathogenesis modeling, drug testing and disease marker identification. Hum. mol. gen. 20, 4851-4864, (2011).
  15. Kim, C. et al. Studying arrhythmogenic right ventricular dysplasia with patient-specific iPSCs. Nature 494, 105-110, (2013)
  16. Hick, A. et al. Neurons and cardiomyocytes derived from induced pluripotent stem cells as a model for mitochondrial defects in Friedreich's ataxia. Dis. Model. Mech. 6, 608-621, (2013).
  17. Jiang, Y. et al. An induced pluripotent stem cell model of hypoplastic left heart syndrome (HLHS) reveals multiple expression and functional differences in HLHS-derived cardiac myocytes. Stem cells transl. med. 3, 416-423, (2014).
  18. Carvajal-Vergara, X. et al. Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature 465, 808-812, (2010).
  19. Hankowski, K. E., Hamazaki, T., Umezawa, A. & Terada, N. Induced pluripotent stem cells as a next-generation biomedical interface. Lab. Invest. 91, 972-977, (2011).
  20. Karpel, M.E., Boutwell C.L. & Allen T.M. BLT humanized mice as a small animal model of HIV infection. Curr. Opin. Virol. 13, 75-80, (2015)
  21. Lian, X. et al. Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/beta-catenin signaling under fully defined conditions. Nat. protoc. 8, 162-175, (2013).
  22. Fonoudi, H. et al. A Universal and Robust Integrated Platform for the Scalable Production of Human Cardiomyocytes from Pluripotent Stem Cells. Stem cells transl. med. 4, 1482-1494, (2015).
  23. Guyette, J. P. et al. Bioengineering Human Myocardium on Native Extracellular Matrix Novelty and Significance Circ. Res. 118, 56-72, (2016).
  24. Bao, X. et al. Long-term self-renewing human epicardial cells generated from pluripotent stem cells under defined xeno-free conditions. Nat. Biomed. Eng. 1, 0003, (2016)
  25. Mital, S. in Etiology and Morphogenesis of Congenital Heart Disease: From Gene Function and Cellular Interaction to Morphology (eds Toshio Nakanishi et al.) 321-327 (Springer Japan, 2016).
Go to the profile of Thamarasee Jeewandara

Thamarasee Jeewandara

Research Associate , CUNY/Einstein Coll. Med.

Bioengineering, biochemistry and molecular biology

No comments yet.